Boji Medical Technology Co Ltd
SZSE:300404

Watchlist Manager
Boji Medical Technology Co Ltd Logo
Boji Medical Technology Co Ltd
SZSE:300404
Watchlist
Price: 8.69 CNY -6.16% Market Closed
Market Cap: 3.3B CNY
Have any thoughts about
Boji Medical Technology Co Ltd?
Write Note

Boji Medical Technology Co Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Boji Medical Technology Co Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Boji Medical Technology Co Ltd
SZSE:300404
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Boji Medical Technology Co Ltd
Glance View

Market Cap
3.3B CNY
Industry
Life Sciences Tools & Services

Boji Medical Technology Co., Ltd. is a contract research organization(CRO) that offers outsourcing drugs research and development services, including new drugs evaluation and clinical trials, preclinical studies and researches, medical devices registration, data management, biostatistics and other consultation services. The company is headquartered in Guangzhou, Guangdong and currently employs 989 full-time employees. The company went IPO on 2015-04-24. The firm mainly provides one-stop CRO services for the development and production of new drugs and medical devices for domestic and foreign pharmaceutical companies and other research institutions. The firm's CRO services include pre-clinical research services, clinical research services, other consulting services, pharmaceutical Contract Development Manufacture Organization (CDMO) services, pre-clinical independent research and development services, and technology achievement transformation services. The firm mainly conducts its businesses in the domestic market.

Intrinsic Value
9.32 CNY
Undervaluation 7%
Intrinsic Value
Price

See Also

Back to Top